

IN THE CLAIMS:

1.-110. (Cancelled)

111. (Previously Presented) A purified antibody or antigen binding fragment thereof, wherein said antibody or said antigen binding fragment specifically binds to an epitope of a polypeptide having an approximate molecular weight of 115 kDa using sodium dodecyl sulfate polyacrylamide gel electrophoresis, wherein said polypeptide is expressed by ASPC-1 (ATCC Accession No. CRL-1682) or BXPC-3 (ATCC Accession No. CRL-1687) cells and wherein PM-2 antibody produced by a cell line deposited as DSM ACC2600 specifically binds to said epitope of the polypeptide having an approximate molecular weight of 115 kD expressed by ASPC-1 (ATCC Accession No. CRL-1682) or BXPC-3 (ATCC Accession No. CRL-1687) cell.

112. (Currently Amended) The purified antibody or ~~functional antigen binding~~ antigen binding fragment thereof of claim 111, wherein said antibody or said ~~functional antigen binding~~ antigen binding fragment comprises a sequence at least 90% identical to the sequence of SEQ ID NO:5 or comprises a sequence at least 90% identical to the sequence of SEQ ID NO:7.

113. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antibody or said antigen binding fragment comprises a sequence at least 95% identical to the sequence of SEQ ID NO:5 or comprises a sequence at least 90% identical to the sequence of SEQ ID NO:7.

114. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antibody or said antigen binding fragment comprises a sequence at least 90% identical to the sequence of SEQ ID NO:5 or comprises a sequence at least 95% identical to the sequence of SEQ ID NO:7.

115. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antibody or antigen binding fragment thereof is at least 98% identical to the full length of sequence SEQ ID NO:5 or SEQ ID NO:7.

116. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antibody or said antigen binding fragment comprises a sequence at least 95% identical to SEQ ID NO:5 or comprises a sequence at least 95% identical to SEQ ID NO:7.

117.-119. (Cancelled)

120. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antibody or said antigen binding fragment comprises SEQ ID NO:5 and SEQ ID NO:7 with a conservative amino acid substitution in either SEQ ID NO:5 or SEQ ID NO:7.

121. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antigen binding fragment comprises a fragment that includes amino acids 26-34, 52-58 and 97-103 of SEQ ID NO:5, and includes amino acids 11-18, 36-43, and 82-100 of SEQ ID NO:7.

122. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antigen binding fragment comprises a fragment that includes amino acids 26-34, 52-58 and 97-103 of SEQ ID NO:5, or that includes amino acids 11-18, 36-43, and 82-100 of SEQ ID NO:7.

123. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antibody or antigen binding fragment thereof comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:7.

124. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antigen binding fragment is selected from the group consisting of F_v, Fab, Fab', and F(ab')₂.

125. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antibody or said antigen binding fragment is linked or conjugated to a detectable agent.

126. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antibody or antigen binding fragment thereof specifically binds to a stomach adenocarcinoma, colorectal adenocarcinoma, squamous cell lung carcinoma, lung adenocarcinoma, squamous cell carcinoma of the esophagus, adenocarcinoma of the pancreas, urothel carcinoma of the urinary bladder, renal cell carcinoma of the kidney, adenocarcinoma of the prostate, ductal carcinoma of the breast, lobular carcinoma of the breast, adenocarcinoma of the ovary, adenocarcinoma of the endometrium, or adenocarcinoma of the uterus cell.

127. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antibody or antigen binding fragment thereof specifically binds to and inhibits proliferation of adenocarcinoma cells of the pancreas in vitro.

128. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antibody or antigen binding fragment thereof inhibits proliferation of BXPC-3 (ATCC Accession No. CRL-1687) cells.

129. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antibody or antigen binding fragment thereof induces apoptosis of BXPC-3 (ATCC Accession No. CRL-1687) cells.

130. (Previously Presented) The purified antibody or antigen binding fragment thereof of claim 111, wherein said antibody or antigen binding fragment thereof specifically binds to CACO-2 cell line (ATCC Accession No. HBT-37), COLO-320 cell line (DSMZ Accession No. ACC 144), or COLO-206F cell line (DSMZ Accession No. ACC 21).

131.-132. (Cancelled)

133. (Previously Presented) A purified antibody or antigen binding fragment thereof, comprising the amino acid sequence of SEQ ID NO:5 and SEQ ID NO:7.

134. (Previously Presented) An antibody produced by the PM-2 cell line having DSMZ Accession No. DSM ACC2600.

135.-154. (Cancelled)